Recent advances in epigenetic therapeutics for Rett syndrome: from mechanisms to clinical trials
Frontiers in Behavioral Neuroscience · 30.06.2026 · 20
DOI: 10.3389/fnbeh.2026.1835425 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Behavioral Neuroscience, online erschienen am 30.06.2026. Verfasst von Cuijie Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rett syndrome (RTT) stands at the forefront of the genetic therapy revolution. This severe X-linked neurodevelopmental disorder, primarily caused by mutations in the MECP2 gene, was historically considered a static condition but is now recognized as a potentially reversible neurodevelopmental disorder. This review synthesizes recent breakthroughs in our understanding of MeCP2’s role in chromatin architecture, including its involvement in liquid-liquid phase separation (LLPS). We critically examine the transition from conventional symptom management to precision epigenetic therapeutics. Key advances discussed include next-generation gene replacement strategies with autoregulatory control to prevent toxicity, programmable epigenetic editing (e.g., CRISPR-off/on) to correct MECP2 expression endogenously, and novel approaches for X-chromosome reactivation (XCI). Furthermore, we propose a stratified therapeutic framework (genotype-guided therapies) based on specific mutation types. Finally, we analyze data from ongoing clinical trials and highlight the remaining hurdles—such as delivery efficiency, immunogenicity, and the urgent need for objective biomarkers—that must be overcome to translate these epigenetic innovations into a cure.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, The First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
- School of Pediatrics, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Zitieren
APA
Zhao, C., Huang, Z., Li, R., Hua, L., Li, H., & Wang, B. (2026). Recent advances in epigenetic therapeutics for Rett syndrome: from mechanisms to clinical trials. Frontiers in Behavioral Neuroscience, 20. https://doi.org/10.3389/fnbeh.2026.1835425
Vancouver
Zhao C, Huang Z, Li R, Hua L, Li H, Wang B. Recent advances in epigenetic therapeutics for Rett syndrome: from mechanisms to clinical trials. Frontiers in Behavioral Neuroscience. 2026;20. doi:10.3389/fnbeh.2026.1835425
BibTeX
@article{Zhao2026,
author = {Zhao, Cuijie and Huang, Zhuo and Li, Ruixing and Hua, Lei and Li, Huawei and Wang, Bocai},
title = {Recent advances in epigenetic therapeutics for Rett syndrome: from mechanisms to clinical trials},
journal = {Frontiers in Behavioral Neuroscience},
year = {2026},
volume = {20},
doi = {10.3389/fnbeh.2026.1835425}
}
EUVIMED